Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids

Esophageal remodeling occurs in eosinophilic esophagitis (EE) patients but whether the components of remodeling in the subepithelium are reversible by administration of topical oral corticosteroids is unknown. We quantitated the degree of lamina propria remodeling in esophageal biopsies obtained bef...

Full description

Saved in:
Bibliographic Details
Published inAllergy (Copenhagen) Vol. 65; no. 1; pp. 109 - 116
Main Authors Aceves, S.S, Newbury, R.O, Chen, D, Mueller, J, Dohil, R, Hoffman, H, Bastian, J.F, Broide, D.H
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.01.2010
Blackwell Publishing Ltd
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Esophageal remodeling occurs in eosinophilic esophagitis (EE) patients but whether the components of remodeling in the subepithelium are reversible by administration of topical oral corticosteroids is unknown. We quantitated the degree of lamina propria remodeling in esophageal biopsies obtained before and after at least 3 months of therapy with budesonide in 16 pediatric EE subjects. In addition, we investigated whether corticosteroid therapy modulated vascular activation (expression of VCAM-1; level of interstitial edema), TGFβ₁ activation (levels of TGFβ₁, phosphorylated Smad2/3), and performed a pilot analysis of a polymorphism in the TGFβ₁ promoter in relation to EE subjects who had reduced remodeling with budesonide therapy. EE subjects were stratified based on the presence (n = 9) or absence (n = 7) of decreased epithelial eosinophilia following budesonide. Patients with residual eosinophil counts of [less-than or equal to]7 eosinophils per high power field in the epithelial space (responders) demonstrated significantly reduced esophageal remodeling with decreased fibrosis, TGFβ₁ and pSmad2/3 positive cells, and decreased vascular activation in association with budesonide therapy. Responders were more likely to have a CC genotype at the -509 position in the TGFβ₁ promoter. Reductions in epithelial eosinophils following budesonide therapy were associated with significantly reduced esophageal remodeling.
Bibliography:http://dx.doi.org/10.1111/j.1398-9995.2009.02142.x
Edited by: Hans‐Uwe Simon
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:0105-4538
1398-9995
1398-9995
DOI:10.1111/j.1398-9995.2009.02142.x